世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

マルチプレックス・アッセイの世界市場予測 2024-2032


GLOBAL MULTIPLEX ASSAY MARKET FORECAST 2024-2032

主な調査結果 世界のマルチプレックスアッセイ市場は、予測期間2024-2032年にCAGR 8.12%を記録する見込みである。市場成長は、政府資金や研究開発活動の増加、従来のアッセイよりもマルチプレックスアッセイが好... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Inkwood Research
インクウッドリサーチ
2024年3月23日 US$2,900
シングルユーザライセンス(印刷不可)
ライセンス・価格情報
注文方法はこちら
298 英語

 

サマリー

主な調査結果
世界のマルチプレックスアッセイ市場は、予測期間2024-2032年にCAGR 8.12%を記録する見込みである。市場成長は、政府資金や研究開発活動の増加、従来のアッセイよりもマルチプレックスアッセイが好まれるようになっていること、個別化医薬品の採用が増加していることなどの主な要因によって促進される。
市場インサイト
マルチプレックスアッセイとは、タンパク質、サイトカイン、生体分子、成長因子、ケモカインなど、複数の分析対象物を同時に検出・定量してプロファイリングする方法である。このアッセイは、ポリメラーゼ連鎖反応(PCR)で複数のターゲットを増幅するために利用され、ELISAなどの従来の方法と比較して、より短時間で微量のタンパク質やその他の分析対象物から付加的な情報を収集する。
マルチプレックスアッセイは、がんや心血管疾患などの治療薬の研究開発において、非常に大きな可能性を秘めている。例えば、ビーズベースのLuminex xMAPマルチプレックスアッセイは、血漿、培養細胞、血清、その他の生物学的サンプルに適合するがんバイオマーカーアッセイのプラットフォームを提供する。米国がん研究協会(AACR)は、受容体型チロシンキナーゼ(RTK)阻害剤に対する後天性耐性の検査に役立つマルチプレックスイムノアッセイを設計した。さらに、RTKはがんを治療するための薬剤開発の標的として利用されている。
地域別インサイト
世界のマルチプレックスアッセイ市場の成長評価には、北米、欧州、アジア太平洋、その他の地域の地理的分析が含まれる。北米は予測期間終了までに最も高い市場シェアを獲得する見込みである。この市場成長は、新薬や治療法の研究開発活動の増加、新しいバイオマーカーを検出するための政府資金の増加、脳卒中や癌のような慢性疾患の発生率の増加といった主要な促進要因によるものである。
競争に関する洞察
世界のマルチプレックスアッセイ市場における競合の激しさは、予測される年数にわたって高止まりすると予想される。同市場に参入している企業は、新製品開発、M&A、提携など、いくつかの戦略を採用して競争に勝ち、市場シェアを維持している。市場に参入している大手企業には、F. Hoffmann-la Roche、Agilent Technologies Inc、Qiagen NVなどがあります。
当レポートの内容は以下の通りです:
- 市場全体に関する主な調査結果
- 市場ダイナミクスの戦略的内訳(促進要因、阻害要因、機会、課題)
- 全セグメント、サブセグメント、地域の3年間の過去データとともに、最低9年間の市場予測
- 市場セグメンテーション:主要セグメントの徹底的な評価と市場予測
- 地域別分析:言及された地域と国レベルのセグメントを市場シェアとともに評価
- 主要分析:ポーターのファイブフォース分析、ベンダーランドスケープ、オポチュニティマトリックス、主要購買基準など。
- 競争環境は、要因、市場シェアなどに基づく主要企業の理論的説明である。
- 企業プロファイリング:詳細な会社概要、提供する製品・サービス、SCOT分析、最近の戦略的展開など


ページTOPに戻る


目次

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON MULTIPLEX ASSAY MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. SOFTWARE AND SERVICES SECTOR EMERGES AS THE RAPIDLY EXPANDING PRODUCT & SERVICE SEGMENT
2.5.2. PROTEIN-BASED MULTIPLEX ASSAY IS THE HIGHEST REVENUE-GENERATING TYPE
2.5.3. RESEARCH & DEVELOPMENT APPLICATIONS DOMINATE MARKET SHARE
2.5.4. MULTIPLEX PCR TECHNOLOGY DEMONSTRATES FASTER GROWTH
2.5.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ARE MAJOR USERS OF MULTIPLEX ASSAYS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. ESCALATING INCIDENCE OF CHRONIC DISEASES
3.1.2. GROWING PREFERENCE FOR MULTIPLEX ASSAYS OVER CONVENTIONAL APPROACHES
3.1.3. INCREASING ACCEPTANCE OF PERSONALIZED MEDICINE
3.2. KEY RESTRAINTS
3.2.1. OVERCOMING THE DIFFICULTY OF ESTABLISHING A SUFFICIENT ASSAY RANGE
3.2.2. CHALLENGES ASSOCIATED WITH CROSS-REACTIVITY AND ASSAY INTERFERENCE
3.2.3. SHORTAGE OF SKILLED PROFESSIONALS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING DRUG DISCOVERY ENDEAVORS
4.1.2. PROGRESS IN ASSAY PLATFORM TECHNOLOGY
4.1.3. RAPID EXPANSION OF COMPANION DIAGNOSTICS
4.2. PORTER’S FIVE FORCES MODEL
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.3.2. GROWTH PROSPECT MAPPING FOR GERMANY
4.3.3. GROWTH PROSPECT MAPPING FOR INDIA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. KEY BUYING CRITERIA
4.6.1. COVERAGE OF ANALYTES
4.6.2. RAPIDITY
4.6.3. ABILITY TO MULTIPLEX
4.6.4. USER-FRIENDLINESS
4.6.5. AUTOMATION POTENTIAL
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT (R&D)
4.7.2. MANUFACTURING AND PRODUCTION
4.7.3. DISTRIBUTION AND SUPPLY CHAIN
4.7.4. CLINICAL APPLICATION AND DATA ANALYSIS
4.7.5. MARKET RESEARCH AND COMMERCIALIZATION
5. MARKET BY PRODUCT AND SERVICE
5.1. REAGENTS AND CONSUMABLES
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. INSTRUMENTS AND ACCESSORIES
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
5.3. SOFTWARE AND SERVICES
5.3.1. MARKET FORECAST FIGURE
5.3.2. SEGMENT ANALYSIS
6. MARKET BY TYPE
6.1. PROTEIN-BASED MULTIPLEX ASSAY
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. NUCLEIC ACID-BASED MULTIPLEX ASSAY
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
6.3. OTHER TYPES
6.3.1. MARKET FORECAST FIGURE
6.3.2. SEGMENT ANALYSIS
7. MARKET BY APPLICATION
7.1. RESEARCH AND DEVELOPMENT
7.1.1. MARKET FORECAST FIGURE
7.1.2. SEGMENT ANALYSIS
7.2. CLINICAL DIAGNOSTICS
7.2.1. MARKET FORECAST FIGURE
7.2.2. SEGMENT ANALYSIS
7.3. COMPANION DIAGNOSTICS
7.3.1. MARKET FORECAST FIGURE
7.3.2. SEGMENT ANALYSIS
8. MARKET BY TECHNOLOGY
8.1. MULTIPLEX PROTEIN MICROARRAY
8.1.1. MARKET FORECAST FIGURE
8.1.2. SEGMENT ANALYSIS
8.2. MULTIPLEX PCR
8.2.1. MARKET FORECAST FIGURE
8.2.2. SEGMENT ANALYSIS
8.3. OTHER TECHNOLOGIES
8.3.1. MARKET FORECAST FIGURE
8.3.2. SEGMENT ANALYSIS
9. MARKET BY END-USER
9.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.1.1. MARKET FORECAST FIGURE
9.1.2. SEGMENT ANALYSIS
9.2. RESEARCH INSTITUTES
9.2.1. MARKET FORECAST FIGURE
9.2.2. SEGMENT ANALYSIS
9.3. CLINICAL LABORATORIES
9.3.1. MARKET FORECAST FIGURE
9.3.2. SEGMENT ANALYSIS
9.4. HOSPITALS
9.4.1. MARKET FORECAST FIGURE
9.4.2. SEGMENT ANALYSIS
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. NORTH AMERICA MULTIPLEX ASSAY MARKET DRIVERS
10.1.3. NORTH AMERICA MULTIPLEX ASSAY MARKET CHALLENGES
10.1.4. KEY PLAYERS IN NORTH AMERICA MULTIPLEX ASSAY MARKET
10.1.5. COUNTRY ANALYSIS
10.1.5.1. UNITED STATES
10.1.5.1.1. UNITED STATES MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.1.5.2. CANADA
10.1.5.2.1. CANADA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2. EUROPE
10.2.1. MARKET SIZE & ESTIMATES
10.2.2. EUROPE MULTIPLEX ASSAY MARKET DRIVERS
10.2.3. EUROPE MULTIPLEX ASSAY MARKET CHALLENGES
10.2.4. KEY PLAYERS IN EUROPE MULTIPLEX ASSAY MARKET
10.2.5. COUNTRY ANALYSIS
10.2.5.1. GERMANY
10.2.5.1.1. GERMANY MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.2. UNITED KINGDOM
10.2.5.2.1. UNITED KINGDOM MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.3. FRANCE
10.2.5.3.1. FRANCE MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.4. ITALY
10.2.5.4.1. ITALY MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.5. SPAIN
10.2.5.5.1. SPAIN MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.6. BELGIUM
10.2.5.6.1. BELGIUM MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.7. POLAND
10.2.5.7.1. POLAND MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.8. REST OF EUROPE
10.2.5.8.1. REST OF EUROPE MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3. ASIA-PACIFIC
10.3.1. MARKET SIZE & ESTIMATES
10.3.2. ASIA-PACIFIC MULTIPLEX ASSAY MARKET DRIVERS
10.3.3. ASIA-PACIFIC MULTIPLEX ASSAY MARKET CHALLENGES
10.3.4. KEY PLAYERS IN ASIA-PACIFIC MULTIPLEX ASSAY MARKET
10.3.5. COUNTRY ANALYSIS
10.3.5.1. CHINA
10.3.5.1.1. CHINA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.2. JAPAN
10.3.5.2.1. JAPAN MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.3. INDIA
10.3.5.3.1. INDIA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.4. AUSTRALIA & NEW ZEALAND
10.3.5.4.1. AUSTRALIA & NEW ZEALAND MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.5. SOUTH KOREA
10.3.5.5.1. SOUTH KOREA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.6. THAILAND
10.3.5.6.1. THAILAND MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.7. INDONESIA
10.3.5.7.1. INDONESIA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.8. VIETNAM
10.3.5.8.1. VIETNAM MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.9. REST OF ASIA-PACIFIC
10.3.5.9.1. REST OF ASIA-PACIFIC MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.4. REST OF WORLD
10.4.1. MARKET SIZE & ESTIMATES
10.4.2. REST OF WORLD MULTIPLEX ASSAY MARKET DRIVERS
10.4.3. REST OF WORLD MULTIPLEX ASSAY MARKET CHALLENGES
10.4.4. KEY PLAYERS IN REST OF WORLD MULTIPLEX ASSAY MARKET
10.4.5. REGIONAL ANALYSIS
10.4.5.1. LATIN AMERICA
10.4.5.1.1. LATIN AMERICA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.4.5.2. MIDDLE EAST & AFRICA
10.4.5.2.1. MIDDLE EAST & AFRICA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
11.2.1. ABCAM
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCT PORTFOLIO
11.2.2. AGILENT TECHNOLOGIES INC
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCT PORTFOLIO
11.2.2.3. STRENGTHS & CHALLENGES
11.2.3. BECTON, DICKINSON AND COMPANY (BD)
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCT PORTFOLIO
11.2.3.3. STRENGTHS & CHALLENGES
11.2.4. BIO-RAD LABORATORIES INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCT PORTFOLIO
11.2.4.3. STRENGTHS & CHALLENGES
11.2.5. BIO-TECHNE CORPORATION
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCT PORTFOLIO
11.2.6. CELLCARTA
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCT PORTFOLIO
11.2.7. F. HOFFMANN-LA ROCHE LTD
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCT PORTFOLIO
11.2.7.3. STRENGTHS & CHALLENGES
11.2.8. ILLUMINA INC
11.2.8.1. COMPANY OVERVIEW
11.2.8.2. PRODUCT PORTFOLIO
11.2.8.3. STRENGTHS & CHALLENGES
11.2.9. MERCK MILLIPORE
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCT PORTFOLIO
11.2.10. OLINK PROTEOMICS AB
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCT PORTFOLIO
11.2.11. QIAGEN NV
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCT PORTFOLIO
11.2.11.3. STRENGTHS & CHALLENGES
11.2.12. RANDOX LABORATORIES LTD
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCT PORTFOLIO
11.2.13. SEEGENE INC
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCT PORTFOLIO
11.2.14. SIEMENS HEALTHINEERS AG
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCT PORTFOLIO
11.2.14.3. STRENGTHS & CHALLENGES
11.2.15. THERMO FISHER SCIENTIFIC INC
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCT PORTFOLIO
11.2.15.3. STRENGTHS & CHALLENGES

 

ページTOPに戻る


 

Summary

KEY FINDINGS
The global multiplex assay market is set to record a CAGR of 8.12% over the forecast period, 2024-2032. The market growth is facilitated by key factors like increased government funding as well as research and development activities, the growing preference for multiplex assays over conventional assays, and the rising adoption of personalized medicines.
MARKET INSIGHTS
A multiplex assay is a procedure in which several analytes, including proteins, cytokines, biomolecules, growth factors, chemokines, and others, are profiled by detecting and quantifying them simultaneously. The assay is utilized to amplify multiple targets in a polymerase chain reaction (PCR) and gather added information from minute quantities of proteins or other analytes in less time compared to traditional methods like ELISA.
Multiplex assays hold tremendous potential in the research and development of drugs for the treatment of diseases such as cancer and cardiovascular diseases. For instance, bead-based Luminex xMAP multiplex assay offers a platform for cancer biomarker assays compatible with plasma, cultured cells, serum, as well as other biological samples. The American Association of Cancer Research (AACR) designed the multiplex immunoassay that assisted in the examination of acquired resistance to receptor tyrosine kinase (RTK) inhibitors. Moreover, RTK is utilized as a target for drug development to treat cancer.
REGIONAL INSIGHTS
The global multiplex assay market growth assessment includes the geographical analysis of North America, Europe, Asia-Pacific, and Rest of World. North America is set to harbor the highest market share by the end of the forecast period. The market growth is attributed to key drivers such as the increasing research and development activities of new drugs as well as treatment options, the rise in government funds for detecting new biomarkers, and the growing incidence of chronic conditions like stroke and cancer.
COMPETITIVE INSIGHTS
The intensity of competitive rivalry within the global multiplex assay market is anticipated to remain high over the projected years. Companies in the market adopt several strategies, including new product developments, mergers and acquisitions, and collaborations, in order to compete and retain their market share. Some of the leading firms operating in the market include F. Hoffmann-la Roche, Agilent Technologies Inc, Qiagen NV, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments



ページTOPに戻る


Table of Contents

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.4.1. IMPACT OF COVID-19 ON MULTIPLEX ASSAY MARKET
2.5. MAJOR MARKET FINDINGS
2.5.1. SOFTWARE AND SERVICES SECTOR EMERGES AS THE RAPIDLY EXPANDING PRODUCT & SERVICE SEGMENT
2.5.2. PROTEIN-BASED MULTIPLEX ASSAY IS THE HIGHEST REVENUE-GENERATING TYPE
2.5.3. RESEARCH & DEVELOPMENT APPLICATIONS DOMINATE MARKET SHARE
2.5.4. MULTIPLEX PCR TECHNOLOGY DEMONSTRATES FASTER GROWTH
2.5.5. PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES ARE MAJOR USERS OF MULTIPLEX ASSAYS
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. ESCALATING INCIDENCE OF CHRONIC DISEASES
3.1.2. GROWING PREFERENCE FOR MULTIPLEX ASSAYS OVER CONVENTIONAL APPROACHES
3.1.3. INCREASING ACCEPTANCE OF PERSONALIZED MEDICINE
3.2. KEY RESTRAINTS
3.2.1. OVERCOMING THE DIFFICULTY OF ESTABLISHING A SUFFICIENT ASSAY RANGE
3.2.2. CHALLENGES ASSOCIATED WITH CROSS-REACTIVITY AND ASSAY INTERFERENCE
3.2.3. SHORTAGE OF SKILLED PROFESSIONALS
4. KEY ANALYTICS
4.1. KEY MARKET TRENDS
4.1.1. RISING DRUG DISCOVERY ENDEAVORS
4.1.2. PROGRESS IN ASSAY PLATFORM TECHNOLOGY
4.1.3. RAPID EXPANSION OF COMPANION DIAGNOSTICS
4.2. PORTER’S FIVE FORCES MODEL
4.2.1. BUYERS POWER
4.2.2. SUPPLIERS POWER
4.2.3. SUBSTITUTION
4.2.4. NEW ENTRANTS
4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
4.3.1. GROWTH PROSPECT MAPPING FOR UNITED STATES
4.3.2. GROWTH PROSPECT MAPPING FOR GERMANY
4.3.3. GROWTH PROSPECT MAPPING FOR INDIA
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. KEY BUYING CRITERIA
4.6.1. COVERAGE OF ANALYTES
4.6.2. RAPIDITY
4.6.3. ABILITY TO MULTIPLEX
4.6.4. USER-FRIENDLINESS
4.6.5. AUTOMATION POTENTIAL
4.7. VALUE CHAIN ANALYSIS
4.7.1. RESEARCH AND DEVELOPMENT (R&D)
4.7.2. MANUFACTURING AND PRODUCTION
4.7.3. DISTRIBUTION AND SUPPLY CHAIN
4.7.4. CLINICAL APPLICATION AND DATA ANALYSIS
4.7.5. MARKET RESEARCH AND COMMERCIALIZATION
5. MARKET BY PRODUCT AND SERVICE
5.1. REAGENTS AND CONSUMABLES
5.1.1. MARKET FORECAST FIGURE
5.1.2. SEGMENT ANALYSIS
5.2. INSTRUMENTS AND ACCESSORIES
5.2.1. MARKET FORECAST FIGURE
5.2.2. SEGMENT ANALYSIS
5.3. SOFTWARE AND SERVICES
5.3.1. MARKET FORECAST FIGURE
5.3.2. SEGMENT ANALYSIS
6. MARKET BY TYPE
6.1. PROTEIN-BASED MULTIPLEX ASSAY
6.1.1. MARKET FORECAST FIGURE
6.1.2. SEGMENT ANALYSIS
6.2. NUCLEIC ACID-BASED MULTIPLEX ASSAY
6.2.1. MARKET FORECAST FIGURE
6.2.2. SEGMENT ANALYSIS
6.3. OTHER TYPES
6.3.1. MARKET FORECAST FIGURE
6.3.2. SEGMENT ANALYSIS
7. MARKET BY APPLICATION
7.1. RESEARCH AND DEVELOPMENT
7.1.1. MARKET FORECAST FIGURE
7.1.2. SEGMENT ANALYSIS
7.2. CLINICAL DIAGNOSTICS
7.2.1. MARKET FORECAST FIGURE
7.2.2. SEGMENT ANALYSIS
7.3. COMPANION DIAGNOSTICS
7.3.1. MARKET FORECAST FIGURE
7.3.2. SEGMENT ANALYSIS
8. MARKET BY TECHNOLOGY
8.1. MULTIPLEX PROTEIN MICROARRAY
8.1.1. MARKET FORECAST FIGURE
8.1.2. SEGMENT ANALYSIS
8.2. MULTIPLEX PCR
8.2.1. MARKET FORECAST FIGURE
8.2.2. SEGMENT ANALYSIS
8.3. OTHER TECHNOLOGIES
8.3.1. MARKET FORECAST FIGURE
8.3.2. SEGMENT ANALYSIS
9. MARKET BY END-USER
9.1. PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.1.1. MARKET FORECAST FIGURE
9.1.2. SEGMENT ANALYSIS
9.2. RESEARCH INSTITUTES
9.2.1. MARKET FORECAST FIGURE
9.2.2. SEGMENT ANALYSIS
9.3. CLINICAL LABORATORIES
9.3.1. MARKET FORECAST FIGURE
9.3.2. SEGMENT ANALYSIS
9.4. HOSPITALS
9.4.1. MARKET FORECAST FIGURE
9.4.2. SEGMENT ANALYSIS
10. GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1. MARKET SIZE & ESTIMATES
10.1.2. NORTH AMERICA MULTIPLEX ASSAY MARKET DRIVERS
10.1.3. NORTH AMERICA MULTIPLEX ASSAY MARKET CHALLENGES
10.1.4. KEY PLAYERS IN NORTH AMERICA MULTIPLEX ASSAY MARKET
10.1.5. COUNTRY ANALYSIS
10.1.5.1. UNITED STATES
10.1.5.1.1. UNITED STATES MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.1.5.2. CANADA
10.1.5.2.1. CANADA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2. EUROPE
10.2.1. MARKET SIZE & ESTIMATES
10.2.2. EUROPE MULTIPLEX ASSAY MARKET DRIVERS
10.2.3. EUROPE MULTIPLEX ASSAY MARKET CHALLENGES
10.2.4. KEY PLAYERS IN EUROPE MULTIPLEX ASSAY MARKET
10.2.5. COUNTRY ANALYSIS
10.2.5.1. GERMANY
10.2.5.1.1. GERMANY MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.2. UNITED KINGDOM
10.2.5.2.1. UNITED KINGDOM MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.3. FRANCE
10.2.5.3.1. FRANCE MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.4. ITALY
10.2.5.4.1. ITALY MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.5. SPAIN
10.2.5.5.1. SPAIN MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.6. BELGIUM
10.2.5.6.1. BELGIUM MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.7. POLAND
10.2.5.7.1. POLAND MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.2.5.8. REST OF EUROPE
10.2.5.8.1. REST OF EUROPE MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3. ASIA-PACIFIC
10.3.1. MARKET SIZE & ESTIMATES
10.3.2. ASIA-PACIFIC MULTIPLEX ASSAY MARKET DRIVERS
10.3.3. ASIA-PACIFIC MULTIPLEX ASSAY MARKET CHALLENGES
10.3.4. KEY PLAYERS IN ASIA-PACIFIC MULTIPLEX ASSAY MARKET
10.3.5. COUNTRY ANALYSIS
10.3.5.1. CHINA
10.3.5.1.1. CHINA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.2. JAPAN
10.3.5.2.1. JAPAN MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.3. INDIA
10.3.5.3.1. INDIA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.4. AUSTRALIA & NEW ZEALAND
10.3.5.4.1. AUSTRALIA & NEW ZEALAND MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.5. SOUTH KOREA
10.3.5.5.1. SOUTH KOREA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.6. THAILAND
10.3.5.6.1. THAILAND MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.7. INDONESIA
10.3.5.7.1. INDONESIA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.8. VIETNAM
10.3.5.8.1. VIETNAM MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.3.5.9. REST OF ASIA-PACIFIC
10.3.5.9.1. REST OF ASIA-PACIFIC MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.4. REST OF WORLD
10.4.1. MARKET SIZE & ESTIMATES
10.4.2. REST OF WORLD MULTIPLEX ASSAY MARKET DRIVERS
10.4.3. REST OF WORLD MULTIPLEX ASSAY MARKET CHALLENGES
10.4.4. KEY PLAYERS IN REST OF WORLD MULTIPLEX ASSAY MARKET
10.4.5. REGIONAL ANALYSIS
10.4.5.1. LATIN AMERICA
10.4.5.1.1. LATIN AMERICA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
10.4.5.2. MIDDLE EAST & AFRICA
10.4.5.2.1. MIDDLE EAST & AFRICA MULTIPLEX ASSAY MARKET SIZE & OPPORTUNITIES
11. COMPETITIVE LANDSCAPE
11.1. KEY STRATEGIC DEVELOPMENTS
11.1.1. MERGERS & ACQUISITIONS
11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
11.1.3. PARTNERSHIPS & AGREEMENTS
11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
11.2.1. ABCAM
11.2.1.1. COMPANY OVERVIEW
11.2.1.2. PRODUCT PORTFOLIO
11.2.2. AGILENT TECHNOLOGIES INC
11.2.2.1. COMPANY OVERVIEW
11.2.2.2. PRODUCT PORTFOLIO
11.2.2.3. STRENGTHS & CHALLENGES
11.2.3. BECTON, DICKINSON AND COMPANY (BD)
11.2.3.1. COMPANY OVERVIEW
11.2.3.2. PRODUCT PORTFOLIO
11.2.3.3. STRENGTHS & CHALLENGES
11.2.4. BIO-RAD LABORATORIES INC
11.2.4.1. COMPANY OVERVIEW
11.2.4.2. PRODUCT PORTFOLIO
11.2.4.3. STRENGTHS & CHALLENGES
11.2.5. BIO-TECHNE CORPORATION
11.2.5.1. COMPANY OVERVIEW
11.2.5.2. PRODUCT PORTFOLIO
11.2.6. CELLCARTA
11.2.6.1. COMPANY OVERVIEW
11.2.6.2. PRODUCT PORTFOLIO
11.2.7. F. HOFFMANN-LA ROCHE LTD
11.2.7.1. COMPANY OVERVIEW
11.2.7.2. PRODUCT PORTFOLIO
11.2.7.3. STRENGTHS & CHALLENGES
11.2.8. ILLUMINA INC
11.2.8.1. COMPANY OVERVIEW
11.2.8.2. PRODUCT PORTFOLIO
11.2.8.3. STRENGTHS & CHALLENGES
11.2.9. MERCK MILLIPORE
11.2.9.1. COMPANY OVERVIEW
11.2.9.2. PRODUCT PORTFOLIO
11.2.10. OLINK PROTEOMICS AB
11.2.10.1. COMPANY OVERVIEW
11.2.10.2. PRODUCT PORTFOLIO
11.2.11. QIAGEN NV
11.2.11.1. COMPANY OVERVIEW
11.2.11.2. PRODUCT PORTFOLIO
11.2.11.3. STRENGTHS & CHALLENGES
11.2.12. RANDOX LABORATORIES LTD
11.2.12.1. COMPANY OVERVIEW
11.2.12.2. PRODUCT PORTFOLIO
11.2.13. SEEGENE INC
11.2.13.1. COMPANY OVERVIEW
11.2.13.2. PRODUCT PORTFOLIO
11.2.14. SIEMENS HEALTHINEERS AG
11.2.14.1. COMPANY OVERVIEW
11.2.14.2. PRODUCT PORTFOLIO
11.2.14.3. STRENGTHS & CHALLENGES
11.2.15. THERMO FISHER SCIENTIFIC INC
11.2.15.1. COMPANY OVERVIEW
11.2.15.2. PRODUCT PORTFOLIO
11.2.15.3. STRENGTHS & CHALLENGES

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

Inkwood Research社のバイオ薬物分野での最新刊レポート

  • 最新刊レポートはありません。

本レポートと同じKEY WORD()の最新刊レポート

  • 本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問


Inkwood Research社はどのような調査会社ですか?


Inkwood Researchは世界40ヶ国以上の国を対象に広範な市場を調査し、世界市場全体を調査したレポートに加え、アジア太平洋地域、欧州、北米などの主要地域や主要国毎のレポートも数多く出版してい... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/20 10:28

158.95 円

165.20 円

201.28 円

ページTOPに戻る